Article in Molecular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Joshua A NasburgDepartment of Pharmacology, School of Medicine, University of California, Davis, California.
Kyle C RouenDepartment of Physiology and Membrane Biology, School of Medicine, University of California, Davis, California.
Connor J DietrichDepartment of Pharmacology, School of Medicine, University of California, Davis, California.
Heesung ShimPhysical and Life Sciences, Lawrence Livermore National Laboratory, Livermore, California.
Miao ZhangDepartment of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, California.
Igor VorobyovDepartment of Pharmacology, School of Medicine, University of California, Davis, California; Department of Physiology and Membrane Biology, School of Medicine, University of California, Davis, California.
Heike WulffDepartment of Pharmacology, School of Medicine, University of California, Davis, California. Electronic address: hwulff@ucdavis.edu.
Funding
Training Program In Basic & Translational Cardiovascular ScienceT32HL086350 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Martin Cadeiras, David A. Liem · 2008 to 2026
$7.1M
In silico Safety PharmacologyR01HL128537 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CLANCY, COLLEEN E, SANTANA, LUIS F · 2016 to 2024
$5.7M
Predoctoral Training in Pharmacological SciencesT32GM099608 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HELL, JOHANNES W · 2012 to 2021
$2.2M
UC Davis Training Program in Chemical BiologyT32GM136597 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHEILA Sue DAVID, Marie C. Heffern · 2021 to 2026
$1.7M
KCa2 Channel Activators for Opioid Use DisorderR21DA056637 · NIDA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI WULFF, HEIKE · 2022 to 2022
NS309 (6,7-dichloro-1H-indole-2,3-dione-3-oxime) is widely used as a pharmacological tool to increase the activity of small- and intermediate-conductance calcium-activated potassium channels. NS309 is assumed to function as a positive allosteric gating modulator. However, its binding site and the molecular details of its action remain unknown. Here, we show that NS309 has a profound effect on the calcium-dependent gating of the intermediate-conductance Ca
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
6,7-Dichloro-1H-indole-2,3-dione-3-oxime functions as a superagonist for the intermediate-conductance Ca · full record | OpenQuestion